Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LNPEP | Q9UIQ6 | 8/20 | 0.53 |
| ▸ | ANPEP | P15144 | 3/20 | 0.53 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.50 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.48 |
| ▸ | NTSR2 | O95665 | 8/20 | 0.48 |
| ▸ | NTSR1 | P30989 | 8/20 | 0.48 |
| ▸ | SORT1 | Q99523 | 7/20 | 0.47 |
| ▸ | NPY1R | P25929 | 1/20 | 0.46 |
| ▸ | NPY2R | P49146 | 1/20 | 0.46 |
| ▸ | NPY4R | P50391 | 1/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11204436 | 0.91 | LNPEP (0.60) | LNPEPANPEPAGTR1AGTR2NTSR2 | |
| SCHEMBL11204440 | 0.91 | LNPEP (0.60) | LNPEPANPEPAGTR1AGTR2NTSR2 | |
| SCHEMBL17287127 | 0.91 | REN (0.51) | LNPEPANPEPAGTR1AGTR2NTSR2 | |
| SCHEMBL29602804 | 0.88 | LNPEP (0.59) | LNPEPANPEPAGTR1AGTR2NTSR2 | |
| Angiotensin Iv SCHEMBL4322224 | 0.87 | LNPEP (0.68) | LNPEPANPEPAGTR1AGTR2NTSR2 | |
| Angiotensin Iv SCHEMBL4322236 | 0.87 | LNPEP (0.68) | LNPEPANPEPAGTR1AGTR2NTSR2 | |
| SCHEMBL4756905 | 0.85 | LNPEP (0.59) | LNPEPANPEPAGTR1AGTR2NTSR2 | |
| SCHEMBL9010597 | 0.85 | LNPEP (0.64) | LNPEPANPEPAGTR1AGTR2NTSR2 | |
| SCHEMBL9010601 | 0.85 | LNPEP (0.64) | LNPEPANPEPAGTR1AGTR2NTSR2 | |
| SCHEMBL17287131 | 0.84 | AGTR1 (0.51) | AGTR1AGTR2NTSR2NTSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9611293-B2 | Synthesis of beta-arrestin effectors | TREVENA, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| WO-2015179349-A2 | SYNTHESIS OF BETA-ARRESTIN EFFECTORS | TREVENA, INC. (US) | 2015-11-26 | — | — | WO | disclosed |
| US-20150329593-A1 | Synthesis of Beta-Arrestin Effectors | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2015-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329593-A1 | Synthesis of Beta-Arrestin Effectors | ARRB1, ADRB1, ADRB3 | LNPEP 3533/4885ANPEP 2516/4885AGTR1 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.